Clinical Trials

Inclusion Criteria:

•  Age ≥ 18 years old.
• Life expectancy ≥ 6 months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• Breast cancer only:
  • Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes).
• Lymphoma only:
  • Incident lymphoma initiating treatment with vincristine.
• Planned minimum of 4 cycles of chemotherapy.
• Written informed consent given.
• Enrollment must be completed prior to receiving the first dose of chemotherapy.

Exclusion Criteria:

• Evidence of central nervous system metastases.
• Evidence of clinically significant peripheral neuropathy as defined by patient report of frequent numbness or tingling in the hands or feet.
• Any uncontrolled serious illness or medical condition that would impact the conduct of the current study. 
• Previous exposure to neurotoxic chemotherapy drugs.
• Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stroke.
• General anesthesia less than one month prior to enrollment.
• Current use of other adjuvant pharmacologic interventions (e.g., duloxetine, gabapentin, pregabalin, venlafaxine) with known or hypothesized effectiveness for treatment or prevention of peripheral neuropathy at study entry.